Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · operational-macro

Cingulate Inc. Reports Q3 2026 Results, Says CTx-1301 NDA Resubmission Expected ...

14 November 2026 · By · Wire by Fusion42

Published

14 November 2026

Topic

operational-macro

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at quiverquant.com →

◆ Verified

Fusion42 · 14 November 2026 · Fusion42 review

Cingulate Inc. plans to resubmit its NDA for CTx-1301, a treatment for ADHD, between December 2026 and January 2027 after addressing FDA chemistry and manufacturing requests. The company has increased commercial readiness and raised capital to extend operations into mid-2027.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it.

◆ ◆ The Wire takeaway

The FDA acceptance window for your ADHD drug NDA is now clearer with a resubmission expected soon. You can prepare to engage commercial partners and investors for launch strategies while navigating the regulatory timeline.

◆ Coverage

2 sources · 14 Nov 2026

◆ Related on Wire

◆ Topics

Biotechnda-resubmissionfda-approvalbiotechadhd-treatmentfundraisingcommercial-readiness